Overview

Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis

Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to investigate whether dexlansoprazole can be as effective as double dose PPI to achieve SSR in high BMI cases with reflux esophagitis in Los Angeles grades A & B.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Treatments:
Dexlansoprazole
Lansoprazole
Criteria
Inclusion Criteria:

- Eligible participants included patients ≥20 years with either overweight (BMI of 25-30
kg/m2) or obese (BMI > 30 kg/m2), who had undergone panendoscopy due to typical
clinical symptoms of either acid regurgitation, heartburn sensation, or both. By the
results of panendoscopy, patients with the severity of grade A or B esophageal reflux,
according to the Los Angeles classification, are enrolled.

Exclusion Criteria:

- Patients are excluded if they have taken antisecretory agents, including histamine-2
receptor antagonist and PPI, within two weeks prior to the panendoscopy. The following
conditions are also excluded: the presence of peptic ulcers, pregnancy, major medical
problems (including hypertension, liver cirrhosis, COPD, asthma, renal failure and
congestive heart failure), or previous gastric surgery. Patients who have an allergy
history to dexlansoprazole or lansoprazole are also excluded.